HAMLET B
Alpha1H builds its scientific case as Phase III gets under way
New insights into the mechanism of action of the anti-cancer drug Alpha1H are published today in Molecular Therapy, a Cell Press journal. The study maps how Alpha1H disrupts the adhesive structures that hold malignant cells together in the tumor and anchor the tumor to the underlying tissue. By targeting adhesion, Alpha1H disrupts the tumor structure, in addition to killing the tumor cells. The findings explain the massive tumor cell shedding observed in treated patients and strengthen the scientific basis for Hamlet BioPharma’s bladder cancer program, with patients now being treated in Phase III.